- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has priced its previously announced underwritten public offering of 9.1M common shares at $11/share, raising gross proceeds of $100.1M. The offer price represents a discount of 4% from the last close price of $11.48 on Monday.
- Underwriters have an option to purchase up to an additional 1.365M common shares.
- Net proceeds will be used to advance EYP-1901 for wet age-related macular degeneration (vision loss disorder), pipeline and commercial programs, and general corporate purposes.
- The offering is expected to close by February 4.
- Price Action: EYPT shares are higher by 8.01% at $12.40 in the pre-market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
